For research use only
| Cat No. | ABC-TC0031 |
| Product Type | Human Kidney Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Kidney |
| Disease | Cancer |
| Product Code | A498 |
Established from the kidney carcinoma of a 52-year-old man in 1973
A-498 cell line is a human epithelial renal carcinoma cell line derived from the primary kidney tumor of a 52-year-old Caucasian male patient diagnosed with clear cell renal cell carcinoma (ccRCC). The cells display polygonal epithelial morphology, adhere tightly in monolayer cultures, and exhibit a hypotriploid karyotype with chromosomal abnormalities. Additionally, the line expresses P2X4 and DEPDC1, which influence mitochondrial and glycolytic pathways, respectively. A-498 is non-tumorigenic and non-metastatic in immunodeficient mice, yet forms histologically distinctive clear cytoplasmic areas when xenografted. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | A498 |
| Species | Human |
| Cat.No | ABC-TC0031 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Kidney |
| Disease | Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Kidney Cancer Cell Lines |
A-498 is a reliable model for studying low-proliferative clear cell RCC and ferroptosis mechanisms. It was recently used to demonstrate that SETD2 knockdown sensitizes cells to erastin via lipid ROS accumulation. Additionally, A-498 supports metabolic targeting studies, including P2X4 receptor involvement in mitochondrial function and DEPDC1’s role in glycolysis regulation, harnessing lipid and energy metabolism vulnerabilities. Furthermore, A-498 serves in preclinical assays testing combination therapies such as amygdalin plus sulforaphane for growth inhibition.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
